News & Updates

In the treatment of advanced retinoblastoma patients with bilateral disease, initial use of eye-preserving therapies appears to be associated with a worse overall survival, especially for those with very large tumours, according to a study.

Using a wearable medical cuff device can facilitate the continuous monitoring of vital signs, physical activity, and complications in patients on intensive treatment regimens for aggressive haematologic malignancies, according to a recent study.

In colon cancer patients receiving curative surgery, undergoing haemodialysis still carries a high risk of postoperative complications despite advancements in perioperative management, a recent study has found.

The vasodilator ifenprodil together with sorafenib has been identified as a new drug combination for hepatocellular carcinoma (HCC) treatment by researchers from the University of Hong Kong (HKU) using clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR-Cas9) screen.

Adding ibrutinib to obinutuzumab in the first-line setting sustains progression-free survival (PFS) benefit in patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic leukaemia (SLL), including patients with high-risk genomic features, according to the final analysis of the iLLUMINATE* trial.

Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.

Low platelet counts, along with low levels of interleukin (IL)-15 and granulocyte-macrophage colony-stimulating factor (GM-CSF), seem to be good prognostic indicators of metastatic disease in patients with pancreatic ductal adenocarcinoma (PDAC), a recent study has found.